RxDoctor Payments Data

Piotr Grabias, MD

Internal Medicine · Webster, MANPI 1508847419

Payments from drug & device makers

$658in general payments, 2019–2025

Across 31 payments — averaging $21.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$273
  • Exact Sciences$193
  • Astellas Pharma US Inc$100
  • Lilly USA, LLC$34
  • AstraZeneca$27
  • Pfizer$19
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$55885%
  • Education$10015%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$658 in reported general payments places this provider in the 80th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$93,285
Medicare patients
353
Services billed
789

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban156$115,399
XifaxanRifaximin15$55,313
FarxigaDapagliflozin Propanediol43$40,935
JardianceEmpagliflozin27$20,273
TrulicityDulaglutide18$19,828
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$12,568
OzempicSemaglutide13$12,253
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$11,525
RybelsusSemaglutide11$10,249
EntrestoSacubitril/Valsartan12$8,219
Tresiba Flextouch U-100Insulin Degludec12$7,335
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate22$5,247
Atorvastatin Calcium405$4,555
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine11$3,960
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$3,662

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$19$115,399156 claims
AstraZenecaFarxiga, Breztri Aerosphere$27$52,46061 claims
Lilly USA, LLCTrulicity$34$19,82818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Webster

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →